Immunomedics receives orphan drug designation for IMMU-132 to treat pancreatic cancer

Immunomedics has received orphan drug designation from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for its IMMU-132 for pancreatic cancer therapy.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionA novel EGFR-targeting ADC, RC68-PY-VC-PAB-MMAE, shows promise as an effective, selective, and safe therapeutic agent for EGFR-positive pancreatic cancer.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 December 2018Source: Acta Pharmaceutica Sinica BAuthor(s): Xi Cao, Ying Hu, Shi Luo, Yuejing Wang, Tao Gong, Xun Sun, Yao Fu, Zhirong ZhangAbstractDue to the critical correlation between inflammation and carcinogenesis, a therapeutic candidate with anti-inflammatory activity may find application in cancer therapy. Here, we report the therapeutic efficacy of celastrol as a promising candidate compound for treatment of pancreatic carcinoma via naïve neutrophil membrane-coated poly(ethylene glycol) methyl ether-block-poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles. Neutrophil ...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
The National Cancer Institute in Rockville, Maryland, has opened an innovative clinical trial for patients with peritoneal mesothelioma that will explore the safety and effectiveness of a novel CAR T-cell therapy. The phase I trial also is being conducted at Washington University in St. Louis. It is aimed at patients whose disease has relapsed after initial chemotherapy treatment. It involves a laboratory modification of a patient’s T cells — a type of white blood cell — that can help the immune system kill the cancer. CAR T-cell therapy is a form of gene therapy that has been highly successful with blood...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Each year, nearly 300,000 patients receive the lifesaving chemotherapy 5-fluorouracil (5-FU) to treat many types of cancer, including colorectal, breast, bowel, skin, pancreatic, and esophageal cancer. While it can be an effective treatment, it doesn?t work for everyone. In fact, up to 30 percent of those who receive the standard dose can have serious, life-threatening [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news
This study aimed to explore the function of HtrA1 in pancreatic cancer cell growth and its underlying mechanism. We found that the expression of HtrA1 was lower in pancreatic cancer tissue compared to the adjacent normal tissue. Consistently, HtrA1 levels were also decreased in two human pancreatic cancer cell lines, PANC-1 and BXPC-3. Moreover, enforced expression of HtrA1 inhibited cell viability and colony formation of PANC-1 and BXPC-3 cells. Overexpression of HtrA1 promoted apoptosis and suppressed migratory ability of tumor cells. On the contrary, siRNA-mediated knockdown of HtrA1 promoted the growth potential of pan...
Source: Brazilian Journal of Medical and Biological Research - Category: Research Tags: Braz J Med Biol Res Source Type: research
Background: Currently, low molecular weight heparin is the guideline endorsed treatment of patients with cancer associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, there are limited data supporting its use in cancer patients.Methods: Patients with cancer associated acute VTE were randomly assigned to receive either apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily or subcutaneous dalteparin (200 IU/kg for 1 month followed by 150 IU/kg once daily) for 6 months. The primary outcome was major bleeding. Secondary outcomes included VTE recurrence and a composite o...
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Management of Challenging Patients and Scenarios Source Type: research
Abstract This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further research in this understudied malignancy. Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer death in some regions. It often presents at an advanced stage, which contributes to poor five-year survival rates of 2%-9%, ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients. Better understanding of the risk factors and...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
CONCLUSIONS: Following treatment, pain and clinical symptoms were improved in a considerable proportion of patients with pancreatic cancer, proving that palliative radiotherapy is feasible for pancreatic cancer. PMID: 30401617 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Conclusions: Imidazole-capped Cetuximab-targeted mesoporous silica nanoparticles are excellent vehicles for the selective delivery of ZnPcOBP to pancreatic cancer cells expressing the EGFR receptor. The novel nanosystem appears to be a suitable agent for photodynamic therapy of pancreatic tumors.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Authors: Mizukami T, Kamachi H, Fujii Y, Matsuzawa F, Einama T, Kawamata F, Kobayashi N, Hatanaka Y, Taketomi A Abstract Pancreatic cancer often has a very poor prognosis, even after complete resection. The recurrence of hepatic and peritoneal metastases is an important prognostic factor; therefore, the development of improved adjuvant therapy is urgently required. Mesothelin is a cell surface glycoprotein whose expression is restricted to a variety of cancer types, including pancreatic cancer. This expression pattern makes mesothelin an attractive target for cancer therapy, and several agents targeting mesothelin ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Pancreas | Pancreatic Cancer | Pharmaceuticals